תבנית:תרופה/פריוויג'ן - Privigen
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | J06BA Immunoglobulins, normal human |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת××-×ר××× - I.V |
| צ×רת ××× ×× | ת×××¡× ×××× ×¤××××, SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Replacement therapy in⢠Primary immunodeficiency syndromes (PID) such as: â congenital agammaglobulinaemia and hypogammaglobulinaemia â common variable immunodeficiency â severe combined immunodeficiency â Wiskott-Aldrich syndrome⢠Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections⢠Children with congenital AIDS and recurrent infectionsImmunomodulation⢠Immune thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgical interventions to correct the platelet count⢠Guillain-Barr? syndrome⢠Kawasaki disease⢠Chronic inflammatory demyelinating polyneuropathy (CIDP)Allogeneic bone marrow transplantation
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| פר×××××'× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | CSL BEHRING AG, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | GENMEDIX , ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 06/2010. ר×ש××× ×ת×ר××: 06/2016 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: פר×××××'× - Privigen
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/פר×××××'× - Privigen}}
×:
{{תר×פ×/פר×××××'× - Privigen
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־31 בינואר 2023 ב־22:21